Drug intelligence / Profile preview

nimotuzumab + paclitaxel

Development stage: Unknown
Lead developer: Biotech Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination therapy consists of nimotuzumab, a humanized anti-EGFR monoclonal antibody, and paclitaxel, a taxane chemotherapy agent. The regimen is primarily used in the treatment of advanced esophageal squamous cell carcinoma (ESCC), with studies showing promising efficacy and acceptable safety profiles. Nimotuzumab targets the epidermal growth factor receptor, which is commonly overexpressed in ESCC and associated with poor prognosis, while paclitaxel works by disrupting microtubule function during cell division.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nimotuzumab + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nimotuzumab + paclitaxel.

Explore the full profile